Skip to content
Brand AI

Hisun Pharmaceutical

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2015

    FDA import ban over data integrity issues

    Due to laboratory data integrity issues at its Taizhou plant, Hisun Pharmaceutical was placed under an FDA import alert in September 2015, 15 active pharmaceutical ingredients were suspended from sale in the United States, and it received a warning letter in 2016; in 2018 it was censured by the Shanghai Stock Exchange for three disclosure violations. The company rectified, and its US market was damaged.

    Source